Acceleration of the Development of Vaccines and Diagnostics for Typhoid Fever using a human challenge model.
In plain English
AI plain-English summaryTyphoid fever kills up to 600,000 people each year, yet diagnosing it in the field relies on inadequate tests, and proving a vaccine works requires huge, expensive field trials. The problem is that researchers lack a simple biological marker—a "correlate of protection"—that tells them whether a vaccine is effective without watching thousands of people get sick. This project will deliberately infect healthy volunteers with *Salmonella* Typhi to build a controlled human infection model. Using that model, the team will test both existing and experimental vaccines to identify those correlates of protection, and will also evaluate new diagnostic tests that detect the bacteria in blood or urine. If successful, this work could unlock a single-dose oral typhoid vaccine currently in development by Emergent Biosolutions, clearing the path to phase III trials. It would also give doctors in endemic regions a reliable diagnostic tool, replacing the guesswork that now hampers treatment and surveillance. The research is applied and translational—its value lies in accelerating vaccine rollout and improving clinical care, not in exploring fundamental biology for its own sake.
View original technical description
View the original record at the funder ↗
Researchers
Related Research
Grants with similar aims, by meaning.
Original classification
Strategic Translation AwardPlain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know